Assessment of Serum Calprotectin as a Novel Biomarker for Patients With Psoriasis

According to a study published in Minerva Medica, patients with psoriasis had a high level of serum calprotectin compared with healthy controls, and this biomarker had high accuracy in identifying patients.

The research took place at the dermatology unit of Magna Graecia University in Catanzaro, Italy, where 45 subjects were enrolled between January 2018 and July 2019. Of these subjects, 32 were patients with psoriasis and 13 were healthy controls. Psoriasis severity was assessed by the Psoriasis Area Severity Index.

Researchers found that patients with psoriasis had a significantly higher body mass index than controls, and that after performing the t test for unpaired data, serum calprotectin was also higher in the patients in comparison to controls. Additionally, because serum calprotectin showed a significant area under the curve after performing the receiver operator characteristic curve analysis, it’s possible serum calprotectin could play a role in finding patients with psoriasis.

“The results showed that serum calprotectin levels were significantly higher in the patient group than in the control group. This result confirms the observations present in the literature,” lead author Elisabetta Scali, Department of Health Sciences, Magana Graecia University of Catanzaro, Italy and co-authors wrote.

Reference
Scali E, Dastoli S, Procopio AC, et al. Evaluation of serum calprotectin as novel biomarker in psoriatic patients: a prospective pilot study. Minerva Med. Published online February 15, 2022. doi:10.23736/S0026-4806.22.08041-7